Gastrointestinal symptoms and liver injury are not uncommon in patients with COVID-19, as stated in the systematic review and meta-analysis reported by Ren Mao and colleagues.[@bib1] However, we have some concerns about the study.

First, when doing pooled analyses of the overall prevalence of abnormal liver chemistry and liver injury, it would be more appropriate to analyse the data stratified by the severity of COVID-19. As stated by the investigators, patients with severe COVID-19 have a greater risk of liver injury than do patients with non-severe COVID-19. Hence, the overall prevalence of increased aminotransferases and liver injury is influenced by the proportion of patients with severe COVID-19 included; the more studies enrolling patients with severe COVID-19 in the meta-analysis, the higher the prevalence of increased aminotransferases and liver injury is likely to be. Consequently, a subgroup analysis based on the severity of COVID-19 is more valuable to assess the prevalence of liver injury than is a pooled analysis.

Second, not all abnormal liver function tests mean that patients with COVID-19 have liver injury.[@bib2], [@bib3] Elevated aminotransferases might partly result from myocardial injury and muscle injury.[@bib2], [@bib3] Some of the studies included in Mao and colleagues\' meta-analysis[@bib1] only reported data for hypertransaminaemia.[@bib4], [@bib5], [@bib6] When doing their pooled analysis of the prevalence of liver injury, Mao and colleagues[@bib1] considered hypertransaminaemia as liver injury. We do not think this is appropriate. As a result, the prevalence of liver injury might be overestimated in patients with COVID-19.
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